Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Celldex Therapeutics  was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.
Company Growth (employees)
Type
Public
HQ
Hampton, US
Size (employees)
196 (est)
Celldex Therapeutics is headquartered in Hampton, US

Key People at Celldex Therapeutics

Anthony S. Marucci

Anthony S. Marucci

Founder, President & CEO
Avery W. Catlin

Avery W. Catlin

SVP & CFO
Tibor Keler

Tibor Keler

Founder, SVP & CSO
Thomas Davis

Thomas Davis

SVP & CMO
Ronald A. Pepin

Ronald A. Pepin

SVP & Chief Business Officer
Harry H. Penner

Harry H. Penner

Co - Founder

Celldex Therapeutics Office Locations

Celldex Therapeutics has offices in Hampton, Branford, Fall River and Needham
Hampton, US (HQ)
220 53 I 78 Frontage Rd
Needham, US
119 4th Ave
Fall River, US
U Mass Dartmouth Center For Innovation & Entrepreneurship 151 Martine St
Branford, US
1a 688 E Main St

Celldex Therapeutics Data and Metrics

Celldex Therapeutics Financial Metrics

Celldex Therapeutics's revenue was reported to be $5.5 m in FY, 2015 which is a 53% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2015)

5.5 m

Revenue growth (FY, 2014 - FY, 2015), %

53%

Net income (FY, 2015)

(127.2 m)

EBIT (FY, 2015)

(129.5 m)

Market capitalization (24-May-2017)

387.8 m

Closing share price (24-May-2017)

3.1

Cash (31-Dec-2016)

42.5 m
Celldex Therapeutics's current market capitalization is $387.8 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Revenue

4.1 m3.6 m5.5 m

Revenue growth, %

(13%)53%

Operating expense total

85.6 m126 m

EBIT

(81.4 m)(122.4 m)(129.5 m)

EBIT margin, %

(1981%)(3414%)(2364%)

Interest expense

927 k927 k

Net Income

(81.6 m)(118.1 m)(127.2 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

169.4 m28 m72.1 m42.5 m

Accounts Receivable

Inventories

Current Assets

305.2 m205 m294.9 m195.6 m

PP&E

10 m10.5 m11.5 m13.2 m

Goodwill

9 m9 m9 m91 m

Total Assets

347.1 m248 m337.6 m383.4 m

Accounts Payable

2.2 m2.6 m1.5 m1.7 m

Current Liabilities

20.4 m24.5 m30.2 m35.2 m

Additional Paid-in Capital

662.7 m672.7 m878.7 m982.3 m

Retained Earnings

(345.7 m)(463.8 m)(591 m)(719.5 m)

Total Equity

319.8 m211.7 m290.1 m265.4 m

Financial Leverage

1.1 x1.2 x1.2 x1.4 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(81.6 m)(118.1 m)(127.2 m)(128.5 m)

Depreciation and Amortization

1.9 m2.4 m3 m3.1 m

Accounts Receivable

Inventories

Accounts Payable

7.2 m1.5 m4.9 m(5 m)

Cash From Operating Activities

(67.7 m)(101.5 m)(98.9 m)(113 m)

Purchases of PP&E

(4.2 m)(1.9 m)(4.9 m)(2.8 m)

Cash From Investing Activities

(77.4 m)(41 m)(50.2 m)68.9 m

Cash From Financing Activities

289.6 m1.2 m193.2 m14.5 m

Interest Paid

1.2 m1.2 m1.2 m
Y, 2016

Financial Leverage

1.4 x

Celldex Therapeutics Market Value History

Celldex Therapeutics Company Life and Culture

You may also be interested in